The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Following the promising multicentre, international Purpose 1 and Purpose 2 clinical trials with lenacapavir for HIV ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in ...

The use of lenacapavir for the prevention of HIV is investigational and has not been determined to be safe or efficacious and is not approved anywhere globally. About Gilead HIV For more than 35 ...

A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) released pivotal Phase 3 trial results for its investigational HIV prevention drug, lenacapavir, which demonstrated a 96% reduction in HIV ...

HIV effort. More people than ever are receiving antiretroviral treatment and have viral suppression. Deaths from AIDS are at ...

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) released pivotal Phase 3 trial results for its investigational HIV prevention drug, lenacapavir, which demonstrated a 96% reduction in HIV ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced TheNew England Journal of Medicine (NEJM) published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating ...